sorafenib has been researched along with Adrenal Cortex Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amendola, D; Bucci, B; Cerquetti, L; Lardo, P; Maggio, R; Petrangeli, E; Pugliese, G; Raffa, S; Stigliano, A; Torrisi, MR; Toscano, V | 1 |
| Chow, ML; Compoginis, G; Crew, AB; Ochoa, MT; Salame, N | 1 |
| Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M | 1 |
| Cicala, MV; Fassina, A; Finco, I; Frigo, AC; Iacobone, M; Mantero, F; Mariniello, B; Pezzani, R; Rosato, A; Rubin, B; Zuccolotto, G | 1 |
1 trial(s) available for sorafenib and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
3 other study(ies) available for sorafenib and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Sorafenib; Tumor Cells, Cultured | 2021 |
Sorafenib Toxicity Mimicking Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Hypersensitivity Syndrome; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Metastasis; Sorafenib | 2019 |
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Child; Child, Preschool; Everolimus; Female; Humans; Infant; Male; Mice; Mice, Knockout; Mice, SCID; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2012 |